{"id":507051,"date":"2020-09-15T17:26:01","date_gmt":"2020-09-15T17:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=507051"},"modified":"2020-09-15T17:26:01","modified_gmt":"2020-09-15T17:26:01","slug":"antiphospholipid-syndrome-aps-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antiphospholipid-syndrome-aps-pipeline-insight-2020_507051.html","title":{"rendered":"Antiphospholipid Syndrome (APS) Pipeline Insight, 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1600158807.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Antiphospholipid Syndrome (APS) Pipeline Insight, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1600158807.jpeg\" alt=\"Antiphospholipid Syndrome (APS) Pipeline Insight, 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Antiphospholipid Syndrome (APS) Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Antiphospholipid Syndrome (APS) market. A detailed picture of the Antiphospholipid Syndrome (APS) pipeline landscape is provided, which includes the disease overview and Antiphospholipid Syndrome (APS) treatment guidelines.<\/div>\n<p style=\"text-align: justify;\">&#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/antiphospholipid-syndrome-aps-pipeline-insight\" target=\"_blank\">Antiphospholipid Syndrome (APS) Pipeline Insight, 2020<\/a><\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Antiphospholipid Syndrome (APS)&nbsp;market. A detailed picture of the&nbsp;Antiphospholipid Syndrome (APS)&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Antiphospholipid Syndrome (APS)&nbsp;treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;Antiphospholipid Syndrome (APS)&nbsp;commercial assessment and clinical assessment of the&nbsp;Antiphospholipid Syndrome (APS)&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Antiphospholipid Syndrome (APS)&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>View full report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/antiphospholipid-syndrome-aps-pipeline-insight\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/antiphospholipid-syndrome-aps-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Antiphospholipid Syndrome (APS) of&nbsp;pipeline development activities&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of&nbsp;Antiphospholipid Syndrome (APS)&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;Antiphospholipid Syndrome (APS)&nbsp;treatment.<\/li>\n<li>Antiphospholipid Syndrome (APS)&nbsp;key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;Antiphospholipid Syndrome (APS)&nbsp;market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Antiphospholipid Syndrome (APS)&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In-depth Antiphospholipid Syndrome (APS) Commercial Assessment of products&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li>Antiphospholipid Syndrome (APS) Clinical Assessment of products&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/antiphospholipid-syndrome-aps-pipeline-insight\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/antiphospholipid-syndrome-aps-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;Antiphospholipid Syndrome (APS)&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Antiphospholipid Syndrome (APS)&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Antiphospholipid Syndrome (APS)&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;Antiphospholipid Syndrome (APS)&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Antiphospholipid Syndrome (APS).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Antiphospholipid Syndrome (APS)&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Antiphospholipid Syndrome (APS) Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Antiphospholipid Syndrome (APS) Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\">3. Antiphospholipid Syndrome (APS)&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">3.1. Antiphospholipid Syndrome (APS) Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\">4. Antiphospholipid Syndrome (APS)&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Antiphospholipid Syndrome (APS)&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Antiphospholipid Syndrome (APS)&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Antiphospholipid Syndrome (APS)&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\">6. Antiphospholipid Syndrome (APS) Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Antiphospholipid Syndrome (APS) Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Antiphospholipid Syndrome (APS) Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Antiphospholipid Syndrome (APS)&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"text-align: justify;\">14. Antiphospholipid Syndrome (APS)&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Antiphospholipid Syndrome (APS)&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\">17. Antiphospholipid Syndrome (APS)&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Antiphospholipid Syndrome (APS)&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Antiphospholipid Syndrome (APS)&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/antiphospholipid-syndrome-aps-pipeline-insight\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/antiphospholipid-syndrome-aps-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight:<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p> <strong>Contact us:<\/strong><br \/> Shruti Thakur<br \/> info@delveinsight.com<br \/> +919650213330<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=antiphospholipid-syndrome-aps-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=antiphospholipid-syndrome-aps-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Antiphospholipid Syndrome (APS) Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Antiphospholipid Syndrome (APS) market. A detailed picture of the Antiphospholipid Syndrome (APS) pipeline landscape &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/antiphospholipid-syndrome-aps-pipeline-insight-2020_507051.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-507051","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=507051"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507051\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=507051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=507051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=507051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}